Oncology is a $250B market with NO dominant player. Our analysis of 5,900 active interventional trials (16.7M total enrollment) reveals a highly fragmented landscape — the top 5 pharma sponsors control only 8% of trials. Unlike GLP-1's Novo/Lilly duopoly, oncology's competitive structure rewards breadth and pipeline depth over focus.
Executive Summary
The global oncology market exceeded $250B in 2025, driven by checkpoint inhibitors, antibody-drug conjugates (ADCs), and next-generation targeted therapies. Yet the competitive landscape remains remarkably fragmented — a stark contrast to the GLP-1 obesity market's Novo Nordisk vs. Eli Lilly duopoly.
This BD Deep Dive analyzes 5,900 active interventional oncology trials from ClinicalTrials.gov, examining sponsor strategy, Phase 3 pipeline density, therapeutic area concentration, and acquisition opportunities for BD teams.
Table of Contents
1. Market Overview & Scale
Oncology is the largest therapeutic area in clinical development, representing approximately 25-30% of all active industry-sponsored clinical trials globally. Our dataset of 5,900 active interventional oncology trials reveals:
| Metric | Value |
|---|---|
| Total Active Trials | 5,900 |
| Total Enrollment (all phases) | 16,706,227 participants |
| Phase 2 Trials | 1,559 (26%) |
| Phase 3 Trials | 468 (8%) |
| Phase 4 Trials | 101 (2%) |
| Phase 2-4 (commercial signal) | 2,068 (35%) |
| Avg Enrollment / Phase 3 Trial | ~650 patients |
The $250B+ oncology market (2025) includes targeted therapies ($80B), immuno-oncology ($70B), chemotherapy ($40B), and supportive care ($60B). With 468 active Phase 3 trials, the pipeline suggests 50-80 new oncology approvals by 2030.
2. Sponsor Landscape
The oncology landscape is dominated by academic institutions and non-profit organizations, with pharma representing a smaller but higher-value segment:
| Category | Examples | Trial Count | % of Total |
|---|---|---|---|
| Academic / Hospital | NCI, MSK, M.D. Anderson, Mayo | ~2,800 | ~47% |
| Non-Profit / Network | EORTC, Alliance, NRG | ~800 | ~14% |
| Pharma (Industry) | Roche, Merck, Pfizer, AZ | ~1,500 | ~25% |
| Biotech | Seagen, Genentech, Gilead | ~400 | ~7% |
| Gov / Other | NIH, DoD | ~400 | ~7% |
Unlike GLP-1 where top 2 sponsors control 63% of trials, oncology's top 5 pharma sponsors control only 8% of all trials. This fragmentation creates acquisition opportunities — the right target can meaningfully shift market share.
3. Phase Pipeline Analysis
The oncology pipeline distribution shows a healthy progression from early to late stage, with Phase 2 trials outnumbering Phase 3 by ~3.3:1 — typical for a high-attrition therapeutic area.
4. Mechanism Trends
Based on intervention names and sponsor descriptions, the top mechanisms in the oncology pipeline include:
| Mechanism | Key Drugs / Modality | Phase 3 Count | Commercial Signal |
|---|---|---|---|
| Anti-PD-1 / PD-L1 | Pembrolizumab, Nivolumab, Atezolizumab | High | ⭐⭐⭐⭐⭐ |
| Antibody-Drug Conjugates (ADCs) | Trodelvy, Datrowix, Padcev, Tivdak | Rapidly growing | ⭐⭐⭐⭐⭐ |
| Anti-CTLA-4 | Ipilimumab, Tremelimumab | Moderate | ⭐⭐⭐ |
| CAR-T | Kymriah, Yescarta, Abecma, Carvykti | Moderate | ⭐⭐⭐⭐ |
| Anti-LAG-3 / Anti-TIGIT | Relatlimab, Tiragolumab | Early | ⭐⭐⭐ |
| Bispecific Antibodies | Emicizumab, Teclistamab | Growing | ⭐⭐⭐⭐ |
| Anti-Angiogenesis | Bevacizumab, Tyrosine kinase inhibitors | High | ⭐⭐⭐⭐ |
ADCs are the fastest-growing mechanism class, with Pfizer/Seagen leading the category. Anti-PD-1 combinations (IO + chemo, IO + ADC) represent the most active clinical strategy. Bispecific antibodies and next-gen checkpoint targets (LAG-3, TIGIT, TIM-3) are the emerging high-potential opportunities.
5. Competitive Benchmarking
The top pharma sponsors in oncology by Phase 3 trial count and strategic focus:
| Company | Key Assets | Strategy | Phase 3 Count |
|---|---|---|---|
| Roche | Tecentriq, Polivy, Trodelvy co-promote | IO + ADC combination | ~12 |
| Merck | Keytruda, Lynparza, Padcev (collab w/ Astellas) | IO backbone across tumors | ~8 |
| Pfizer | Ibrance, Xalkori, Seagen ADCs (Padcev, Tivdak, Tukysa) | ADC expansion post-Seagen | ~6 |
| AstraZeneca | Imfinzi, Tagrisso, Enhertu (collab w/ Daiichi) | IO + targeted combo | ~5 |
| Novartis | Kisqali, Entrectinib, Scemblix | Targeted + cell therapy | ~4 |
6. Market Gaps & Opportunities
Despite 5,900 active trials, significant unmet needs remain:
- CNS penetration: Brain metastases excluded from most trials; BBB-penetrant IO needed
- Immunotherapy resistance: ~60% of patients don't respond to checkpoint inhibitors; next-gen targets (LAG-3, TIGIT, TIM-3) underdeveloped
- Rare cancers: N-of-1 trial design + rare cancer networks needed
- Biomarker-driven trials: PD-L1, TMB, MSI-H panels expanding but ~40% of trials lack biomarker sub-analysis
- Combination complexity: IO + ADC + targeted triple combos need smarter trial designs to manage toxicity
With Pfizer's Seagen acquisition ($43B) validating ADC valuations, mid-stage ADC biotechs with novel payloads (topoisomerase II, DNA-damaging agents) or novel targets (B7-H3, HER3, CEACAM5) are prime acquisition targets at $1-3B valuations.
7. Deal Evaluation
The oncology M&A market is hot. Recent precedent:
| Acquisition | Value | EV/Sales Multiple | Strategic Rationale |
|---|---|---|---|
| Seagen / Pfizer | $43B (2023) | ~11x peak | ADC platform + Padcev |
| Immunomedics / Gilead | $21B (2020) | ~12x peak | Trodelvy ADC |
| Mersana / GSK | up to $1.3B (2022) | N/A | Early-stage ADC platform |
| Kite / Gilead | $11.9B (2017) | ~8x peak | Yescarta CAR-T |
Oncology assets with Phase 2 data command 6-12x peak sales; Phase 1 assets command 3-8x. ADC platforms with clinical proof-of-concept (like Seagen pre-2023) trade at 10-15x due to platform optionality.
8. Strategic Implications for BD Teams
For Big Pharma BD (Merck, Roche, Novartis, AZ)
The oncology market's fragmentation is an opportunity. Unlike GLP-1 where two companies dominate, oncology's top 5 pharma sponsors control only ~30-35% of pharma trials. Strategic priorities:
- ADC bolt-ons — add novel targets or payloads to existing ADC franchise
- IO combination assets — Phase 2 IO + X combinations ready for Phase 3
- Biomarker/companion diagnostic platforms — patient selection is everything
- Cell therapy next-gen — allogeneic CAR-T, CAR-NK, TCR therapies
For Biotech Founders
BD appetite is high for assets de-risked to Phase 2. Key themes:
- Anti-TIGIT / Anti-TIM-3: After LAG-3 success (relatlimab), next checkpoints are high-potential
- Bispecifics with IO backbone: Dual-targeting + checkpoint inhibition
- ADC with non-DXd payloads: PBD, MMAE, and novel warheads; DXd is becoming crowded
- Rare oncology: Pediatric, rare mutations, basket trial strategies
For Investors
Oncology investment returns concentrate in de-risked Phase 2 → Phase 3 transition assets. Watch for:
- Mid-stage ADC biotechs ($1-3B M&A targets)
- IO combination plays (next-gen checkpoint + anti-angiogenesis)
- Biomarker/assay companies — $250B oncology market needs better patient selection
Generate BD Deep Dive reports like this in minutes.
TrialScope pulls CT.gov data, runs AI analysis, and generates professional investment-grade reports with citations.